Brief: Kamada Announces Supply Agreement With Israeli Ministry Of Health For Its Investigational Igg Product For Covid-19 Initial Order Expected To Generate $3.4 Million In Revenue In First Quarter Of 2021

Kamada

19/10/2020 12:03

Oct 19 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA ANNOUNCES SUPPLY AGREEMENT WITH ISRAELI MINISTRY OF
HEALTH FOR ITS INVESTIGATIONAL IGG PRODUCT FOR COVID-19; INITIAL
ORDER EXPECTED TO GENERATE $3.4 MILLION IN REVENUE IN FIRST
QUARTER OF 2021
    * KAMADA LTD - TREATMENT WITH KAMADA'S INVESTIGATIONAL IGG
PRODUCT
WILL BE REGULATED BY ISRAELI MINISTRY OF HEALTH
    * KAMADA LTD - U.S. CLINICAL DEVELOPMENT OF PLASMA-DERIVED
IGG
PRODUCT AS POTENTIAL COVID-19 TREATMENT EXPECTED TO BEGIN EARLY
2021
    * KAMADA LTD - INITIAL ORDER OF IGG PRODUCT PLANNED TO BE
SUPPLIED
DURING BEGINNING OF 2021, SUFFICIENT TO TREAT ABOUT 500
HOSPITALIZED PATIENTS

Source text for Eikon:  ID:nGNX8Fpxlz 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))